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O R I G I N A L A R T I C L E
Androgen receptor agonists increase lean mass,
improve cardiopulmonary functions and extend
survival in preclinical models of Duchenne muscular
dystrophy
Suriyan Ponnusamy1, Ryan D. Sullivan2, Dahui You3, Nadeem Zafar4,
Chuan He Yang4, Thirumagal Thiyagarajan1, Daniel L. Johnson5,
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Abstract
Duchenne muscular dystrophy (DMD) is a neuromuscular disease that predominantly affects boys as a result of mutation(s)
in the dystrophin gene. DMD is characterized by musculoskeletal and cardiopulmonary complications, resulting in shorter
life-span. Boys afflicted by DMD typically exhibit symptoms within 3–5 years of age and declining physical functions before
attaining puberty. We hypothesized that rapidly deteriorating health of pre-pubertal boys with DMD could be due to dimin-
ished anabolic actions of androgens in muscle, and that intervention with an androgen receptor (AR) agonist will reverse
musculoskeletal complications and extend survival. While castration of dystrophin and utrophin double mutant (mdx-dm) mice
to mimic pre-pubertal nadir androgen condition resulted in premature death, maintenance of androgen levels extended the
survival. Non-steroidal selective-AR modulator, GTx-026, which selectively builds muscle and bone was tested in X-linked
muscular dystrophy mice (mdx). GTx-026 significantly increased body weight, lean mass and grip strength by 60–80% over
vehicle-treated mdx mice. While vehicle-treated castrated mdx mice exhibited cardiopulmonary impairment and fibrosis of
heart and lungs, GTx-026 returned cardiopulmonary function and intensity of fibrosis to healthy control levels. GTx-026 elic-
its its musculoskeletal effects through pathways that are distinct from dystrophin-regulated pathways, making AR agonists
ideal candidates for combination approaches. While castration of mdx-dm mice resulted in weaker muscle and shorter sur-
vival, GTx-026 treatment increased the muscle mass, function and survival, indicating that androgens are important for
extended survival. These preclinical results support the importance of androgens and the need for intervention with AR
agonists to treat DMD-affected boys.
†
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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked autosomal
recessive disease affecting 1/3500 to 1/5000 males world-wide,
with 18 000 DMD patients living in the USA (1). DMD is caused
by frameshift or nonsense mutations in the gene dystrophin,
which result in a dysfunctional or partially functional protein (2–
4). The dystrophin protein is part of a sarcolemma protein com-
plex (dystrophin–glycoprotein complex) that protects the muscle
cell membrane from physical trauma during muscle contraction
(5–7). Although the first clinical observation of DMD was made in
1860s, only in 1986 was the gene underlying DMD cloned and
characterized (8). DMD is characterized by progressive musculos-
keletal wasting starting at 3–5 years of age, with patients experi-
encing difficulty in walking and encountering mortality in their
20s and 30s (9–11). Although braces and walkers provide some
support, a loss of ambulation during childhood leads to wheel-
chair confinement, eventual cardiomyopathy, respiratory dys-
function (diaphragm fibrosis) and death (12–14).
Respiratory supportive care in DMD is provided by assisted
ventilator and cough-assisting devices, whereas cardiac care
is provided by ACE inhibitors and b-blockers (15–17).
Glucocorticoids are the standard of care that slows the disease
progression due to their anti-inflammatory effects, which in turn
strengthen muscles and slows the deterioration of physical func-
tion (18). While one drug (Ataluren) has been approved in Europe
for the treatment of DMD, recently an antisense oligonucleotide
eteplirsen (exon-skipping) that restores the reading frame of dys-
trophin at exon 51 was approved in the USA (19,20). Since exon 51
is mutated in 15% of the patients, the drug is expected to modify
the disease condition in this subset of patients.
A direct correlation between higher muscle mass and survival
in patients with cancer cachexia (a disease also characterized by
skeletal muscle wasting) has prompted evaluation of anabolic
agents such as androgens to slow the decline in physical function
in DMD (21). Two pilot studies with the steroidal androgen oxan-
drolone in boys with DMD have demonstrated an improvement
in muscle mass and muscle protein synthetic rate (22). However,
the steroidal backbone, non-selectivity between muscle and sec-
ondary sexual organs, and hepatotoxicity have precluded the
extended use of oxandrolone in DMD. The discovery of non-
steroidal tissue-selective-androgen receptor modulators (SARMs)
offers an alternative to the use of steroidal androgens for improv-
ing muscle quality and function (23). The lead SARM, enobosarm
(GTx, Inc, Memphis, TN, USA), has been shown to cause a signifi-
cant improvement in muscle mass and physical function in
patients suffering from cancer cachexia (24). Since AR agonists
increase lean mass, strength and protein synthesis, targeting the
AR may be useful in treating other muscle wasting diseases and
supports the use of these androgen receptor (AR) agonists as pos-
sible treatments for DMD (25).
Given that androgens are important for the development
and maintenance of muscle, bone and secondary sexual organs
(26,27), we suggest that the decline in physical function in
young boys with DMD is exacerbated by the absence of andro-
gens. Therefore, we hypothesize that treatment with AR ago-
nists will prevent muscle deterioration and protect young DMD
patients from the decline in muscle function.
Here we tested this hypothesis using a potent SARM, GTx-
026 (GTx Inc.; an analog of enobosarm), in preclinical models of
DMD. Of the several SARMs that were developed, the arylpropio-
namide SARM, GTx-024 (or enobosarm), is clinically the most
advanced (23,28). Multiple cancer cachexia phase II and III
clinical trials have established the efficacy of GTx-024 for
improving muscle mass and physical function (28). The potent
anabolic activity of SARMs (muscle and bone beneficial effects)
with minimum to no androgenic activity (effects on secondary
sexual organs and virilization) confers them advantage over
steroidal androgens (29). We used a mouse model (X-linked
muscular dystrophy mouse) where mutation in dystrophin
causes a frame-shifted dysfunctional protein (mdx) to evaluate
the effects of GTx-026 on muscle mass, function, and cardiopul-
monary anatomy and physiology in the absence of endogenous
androgens. Utrophin (utrn) is an ortholog of dystrophin that parti-
ally compensates for the loss of dystrophin and its expression
in mdx mice is considered as one of the reasons for the milder
phenotype in mdx mice (30–34). Thus, as the phenotype of mdx
mice is mild, we also studied double mutant mice [dmd/utrn
double mutant (mdx-dm)], where both dystrophin and utrophin
(mutation in exon 7) are mutated, which more closely represent
the human clinical condition. GTx-026 potently increased body
weight, lean mass and grip strength in castrated mdx mice.
Echocardiogram studies indicate that the 16-week-old castrated
mdx mice had cardiac and pulmonary anatomical and physio-
logical impairments that were significantly improved by GTx-
026. In addition, treatment of castrated mdx-dm mice with
GTx-026 improved body weight, lean mass, muscle function
and survival. Overall, the AR ligands have impressive effects in
preclinical models of DMD and these studies could become an
impetus for clinical development of an AR agonist for DMD.
Results
Circulating androgens are important for survival
To test our hypothesis that the absence of circulating androgens
leads to accelerated deterioration of skeletal muscle in DMD, we
sham-operated or castrated mdx-dm mice. Since, mdx mice sur-
vive comparably to wild-type mice, we chose mdx-dm mice that
live only for 15–20 weeks (35–37). We measured body weight,
body composition and monitored their survival. Sham-operated
mdx-dm mice modestly gained body weight and lean mass by
20% from the initiation of the study and maintained these
increases throughout the 6-week study period (Fig. 1A). In con-
trast, castrated mdx-dm mice lost body weight and lean mass by
20% (P< 0.01) (Fig. 1A). Almost 66% of the castrated mdx-dm
mice died within 6 weeks of the study initiation, while only 25%
of the sham-operated mice died during the same period (Fig.
1B). This indicates that circulating androgens are important for
the maintenance of body weight and lean mass and are critical
for the survival of mdx-dm mice.
We understood that there are no perfect preclinical models
to represent pre-pubertal conditions. Although slowly maturing
dog or pig models are available, they are expensive and they
lack comprehensive understanding (38). Surge in hormonal lev-
els initiate puberty. We decided to retain the androgen levels in
our studies at lower levels for two reasons; to mimic pre-
pubertal hormonal condition and to evaluate the effect of
SARMs in the absence of endogenous hormonal influence.
We measured serum testosterone in castrated and intact
mice at 4, 8 and 12 weeks of age that corresponds to the experi-
mental duration. While intact or sham operated mice had a
surge in serum testosterone from 20 to 30 ng/dl at 4 weeks of
age to 150–200 ng/dl at 12 weeks of age, the castrated mice
exhibited the serum testosterone levels of around 25 ng/dl
through the 8-week period (Fig. 1C), which correspond to pre-
pubertal range of 7–30 ng/dl.
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SARMs potently activate the AR
To determine if AR agonists can rescue the detrimental pheno-
type caused by the absence of androgens, we conducted studies
with non-steroidal SARMs that have the ability to maximally
activate the AR. We chose these SARMs from the arylpropiona-
mide class and performed transactivation experiments using a
tissue culture system to assess their effects on AR transactiva-
tion. Several advantages favored the continued use of SARMs in
our studies (such as, the non-steroidal backbone, selectivity to
muscle and bone, lack of hepatotoxicity etc.). Moreover, DHT, a
potent steroidal androgen, can be enzymatically inactivated to
weaker androgens or estrogens (39,40). Previous studies have
demonstrated beneficial effects of a SARM in mdx mice (25).
Here, the three arylpropionamide SARMs that bind to the AR
ligand-binding domain (LBD) with Ki between 2 and 10 nM were
tested in HEK-293 cells using a luciferase assay. All three SARMs
were extremely potent in increasing the AR transactivation in
nanomolar concentration, with GTx-026 being the most potent
of the three tested (Fig. 2A, left panel).
An intracellular milieu of coactivators and corepressors reg-
ulate the potency of nuclear receptor ligands (41). In order to
evaluate whether a muscle cell environment will alter the effi-
cacy of GTx-026, a transactivation assay was also performed
with GTx-026 in undifferentiated C2C12 myoblasts. GTx-026
was extremely potent in activating the AR in C2C12 cells (Fig.
2A, right panel). This result shows that GTx-026 is potent in a
muscle cell environment.
SARMs increased lean mass, function and body weight
of wild-type mice
C57BL6/J male mice (6 weeks old; n¼ 6/group) were castrated to
remove the interference of circulating androgens and were
treated subcutaneously with vehicle or 10 mg/kg/day GTx-026.
After 1 week, GTx-026 treatment caused a greater increase in
body weight (67% vs 33% in vehicle-treated mice) and lean mass
(64% vs 31% in vehicle-treated mice) compared with vehicle
treatment. These differences were maintained for the experi-
mental duration (Supplementary Material, Fig. S1A). Grip
strength, which was used as a measure of muscle function, was
also increased by GTx-026 (Supplementary Material, Fig. S1A).
All these increases were statistically significant at P< 0.001.
GTx-026 increased lean mass, body weight and grip
strength in mdx mice
Dystrophin homozygous mutated/utrn heterozygous mutated
mice purchased from JAX labs were bred in-house to generate
the male Dystrophin mutant/utrn wild-type (mdx) mice used in
these studies. Four weeks old male mice were castrated and
treated subcutaneously with either vehicle or 10 mg/kg/day
GTx-026. Body weight and composition were measured weekly.
Grip strength of fore- and hind-limbs was recorded at the begin-
ning of the study and again after 6 and 12 weeks of treatment.
After 2 weeks, the body weights of the GTx-026-treated mice
were greater than those of the vehicle-treated mice, with this
difference increasing in magnitude throughout the duration of
the study (62% in GTx-026-treated mice vs 31% in vehicle-
treated mice; P< 0.001) (Fig. 2B). GTx-026 treatment also
increased lean mass (20% vs 60%; P< 0.001) compared with
vehicle treatment. Consistent with the increase in lean mass,
grip strength also increased in the GTx-026-treated animals (Fig.
2B). These results were reproduced with the other two SARMs,
GTx-024 and GTx-027, indicating that these effects are SARM-
dependent (Supplementary Material, Fig. S1B).
Glucocorticoids are the standard of care in DMD.
Glucocorticoids act through glucocorticoid receptor (GR) to
mediate their anti-inflammatory effects that result in
Figure 1. Circulating androgens improve muscle mass and survival in Dystrophin/utrophin double mutant mice. Dystrophin/utrophin (dmd/utrn) double mutant mice (n¼6
in sham-operated and 8 in castrated group; 4 weeks old) were sham-operated or castrated and weekly body weight (A, left panel) and lean mass (A, right panel) by MRI
were measured and their survival monitored (B). (C) Serum testosterone levels were measured in sham-operated or castrated mdx mice aged 4, 8 and 12 weeks (n¼4/
time point) using ELISA. Values are represented as average 6 SE. *Significance at P<0.01.
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Figure 2. Selective androgen receptor modulator (SARM), GTx-026, increases muscle mass and strength in mdx mice. (A). GTx-026 is a potent activator of the androgen
receptor (AR). AR transactivation studies were performed in HEK-293 cells (left panel) or C2C12 cells (right panel) by transfecting 25 ng CMV-hAR, 0.25 lg GRE-LUC and
10 or 20 ng CMV-renilla-LUC. Twenty-four hours after transfection, cells were treated with vehicle, R1881 or three SARMs (left panel) or GTx-026 (right panel). Cells
were harvested 48 h after transfection and luciferase assay was performed. (B) GTx-026 increases muscle mass and strength in mdx mice. Male mdx mice (4 weeks of
age; n¼6/group) were castrated to reduce the circulating androgens and treated with vehicle or 10 mg/kg/day s.c. of GTx-026. Weekly body weight and MRI to measure
the muscle mass were recorded. Grip strength was measured at the start of the experiment, and after 6 and 12 weeks. Values are represented as percent change from
baseline. *P<0.001 (body weight and muscle mass) and P<0.05 (grip strength). (C) GTx-026 improves prednisolone effects on body weight and muscle mass in castrated
mdx mice. Castrated mdx mice (n¼5/group) were treated with vehicle, prednisolone (5 mg/kg/day p.o.) or GTx-026 (10 mg/kg/day s.c.) or combination of prednisolone
and GTx-026 for 6 weeks. Body weight, body composition and grip strength were measured at the beginning of the study and at weeks 3 and 6. *P<0.01. (D) Clinically
comparable doses of GTx-026 improve body weight and lean mass in mdx mice. Castrated mdx mice (n¼6/group) were treated orally with vehicle or indicated doses of
GTx-026. Body weight and composition were measured at the beginning of the study and after 3, 6 and 9 weeks of dosing. *P<0.001. RLU, relative light units; mpk, milli-
grams per kilogram.
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strengthening of muscle. Glucocorticoids and androgens share
a common pool of coactivators and bind to several overlapping
regulatory cis elements. We tested the effect of combination of
a glucocorticoid, prednisolone, and GTx-026 and compared
the effects with that produced by individual treatments.
Prednisolone at 5 mg/kg oral dose significantly reduced the body
weight and lean mass compared with vehicle-treated mice,
while GTx-026 increased the body weight and lean mass of cas-
trated mdx mice (Fig. 2C). Mice that were treated with a combi-
nation of prednisolone and GTx-026 exhibited body weight and
muscle mass that were comparable to that of vehicle-treated
mice, i.e. neither increased nor decreased (Fig. 2C). This result
indicates that the AR and GR agonists reverses the negative
and positive effects, respectively, of the other treatment.
Interestingly, both GTx-026 and prednisolone increased grip
strength individually, while the combination produced similar
effect. This study indicates that combining an AR agonist with a
GR agonist may be beneficial to stabilize the muscle mass and
body weight that will be reduced by a GR agonist, without
affecting the muscle function. However, additive or synergistic
effects may not be obtained from the combination treatment.
As patients with DMD exhibit pathologic signs as early as 3–
5 years of age when no circulating androgens can be detected,
we performed the majority of our experiments in castrated
male mice to replicate pre-pubertal androgenic environment.
However, since DMD is not reversed by the onset of puberty, we
also studied the effects of GTx-026 in sham-operated intact
male mice. After 2 weeks of treatment, GTx-026-treated mdx
mice had increased lean mass compared with vehicle-treated
mdx mice (20%) and this difference was maintained for
6 weeks (Supplementary Material, Fig. S2). However, by 8 weeks
of treatment (12 weeks of age), the difference in lean mass was
no longer apparent, which could be due to the presence of
endogenous androgens. Concurrent with this increase in lean
mass, grip strength (represented as percent change from base-
line) also increased in mice treated with GTx-026 (150% vs 50%
in vehicle-treated mice) compared with the vehicle-treated mdx
mice (Supplementary Material, Fig. S2).
The dose (10 mg/kg/day s.c.) used in the studies was much
higher than the clinical doses of 3, 9 and 18 mg of enobosarm
(GTx-024) used in cancer cachexia or breast cancer clinical trials.
To ensure that lower clinically comparable doses of GTx-026
have the ability to increase muscle mass in mdx mice, we
treated castrated mdx mice with 0.5, 2.5 and 5 mg/kg/day of
GTx-026 orally. These doses are in the clinical dose range of 3, 9
and 18 mg. GTx-026 significantly and dose-dependently
increased body weight and lean mass at all doses (P< 0.001) (Fig.
2D). These studies indicate that clinically relevant doses will be
sufficient to provide anatomical and physiological improve-
ments in DMD.
Gastrocnemeous and soleus muscle from GTx-026-
treated mice had lower incidence of centrally nucleated
cells and fibrosis
One of the hallmarks of impaired muscle regeneration is the
presence of centrally nucleated cells (42). While healthy muscle
cells have nuclei in the periphery, muscle from DMD patients
and mdx mice have centrally located nuclei. H&E stained soleus
and gastracnemeous sections from castrated mdx mice exhib-
ited 90–95% centrally nucleated cells, while the sections from
wild-type mice had few to no centrally nucleated cells (P< 0.01)
(Fig. 3A). Treatment with GTx-026 partially reduced the number
of centrally nucleated cells to 50–55% from 90 to 95% in
vehicle-treated sections, indicating a potential improvement in
regeneration of muscle fibers.
The extent of fibrosis was evaluated in Mason trichrome-
stained soleus and gastrocnemeous sections and a score of 0–3
was provided based on the intensity and extent of staining.
Soleus and gastrocnemeous muscle of vehicle-treated castrated
mdx mice (n¼ 4 mice and 2 sections/mouse) had substantially
higher fibrosis scores, close to 3 in several cases, while those
from mice treated with GTx-026 had a lower fibrosis scores (Fig.
3B). The same trend was observed in the number of necrosed
cells (Fig. 3B), while no differences in the number of inflamma-
tory cell infiltration was observed between vehicle- and GTx-
026-treated muscles.
Staining for fast and slow fibers in gastrocnemeous muscle
showed that majority of the cells and fibers had the characteris-
tics of fast fibers. SARM-treatment did not alter the characteris-
tics of the fiber or cell subtype.
GTx-026 and dystrophin regulate distinct pathways in
mdx mice
To determine the mechanism of GTx-026 action, RNA sequenc-
ing studies were performed in gastrocnemeous muscle from
castrated vehicle-treated wild-type mice and castrated vehicle-
or GTx-026-treated mdx mice (n¼ 3/group). Dysfunctional dys-
trophin altered the expression of 417 genes compared with
wild-type mice (Fig. 4B). Most up-regulated genes in mdx mice
include prune-2, Igfn-1, Mettl21e, IGF-2 and Ahnak-2 and the most
down-regulated genes include Dusp-26, Gcsh, ppp1r1a, htra4 and
Dmd. Ingenuity pathway analysis (IPA) of the genes significantly
enriched in mdx mice compared with wild-type mice shows that
the top canonical signaling pathway altered is neuronal nitric
oxide synthase (nNOS) signaling (43) and creatinine biosynthe-
sis, while the top upstream regulators are all myoanabolic path-
way markers such as Dmd, Myod1 and Myog. Moreover, IPA
showed that the biological functions of genes enriched in mdx
mice represent neurological diseases, respiratory diseases, and
skeletal and muscular disorder, and developmental disorder.
These indicate that there is a good correlation between the
expression of these genes and the phenotype of mdx mice.
Genes regulated by GTx-026 in castrated mdx mice were
compared with that of castrated vehicle-treated mdx mice (Fig.
4A). Interestingly, only 60 genes were differentially regulated by
GTx-026, which is a much smaller subset compared with the
genes altered in prostate by AR ligands. Most up-regulated
genes include Inmt, Kcng4, Amd1, Amd2, pla1a, while the most
down-regulated genes include Casr, Grmd1b, Mybph and
MAPK8ip1. IPA analysis indicates that GTx-026 enriched genes
that belong to two highly relevant canonical pathways, sper-
mine and spermidine biosynthesis (44). These two pathways
play important roles in skeletal muscle hypertrophy and atro-
phy (45). The genes that are enriched by GTx-026 mediate the
biological functions of connective tissue disorder, skeletal
muscle disorder and developmental disorder. Interestingly,
there was minimum to no overlap between genes regulated by
dystrophin mutation and the genes regulated by GTx-026 treat-
ment, indicating that GTx-026 does not function by reversing
the pathways de-regulated by dystrophin mutation. This makes
AR agonists like GTx-026 a candidate for combination therapy
with exon-skipping drugs and others.
MicroRNAs are non-coding RNAs that are 22–24 nucleotides
long. miRNAs are critical for the physiology and pathology of
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multiple tissues. miRNAs play pivotal role in musculoskeletal equi-
librium and pathogenesis (46–48). Using Nanostring technology, we
measured the miRNAs in the same sample set used for RNA-
sequencing (Fig. 4C). Dystrophin mutation modified the expression
of 10 miRNAs, which were not reversed by GTx-026 treatment.
Alternatively, GTx-026 had modest effect on miRNA expression
modifying the expression of only 4 miRNAs (Fig. 4C, right panel).
GTx-026 protects hearts of castrated mdx mice from
pathological transformation
One of the primary causes of death in DMD patients is cardiac
and respiratory insufficiencies due to weakening of the respective
muscles (14,16,37). Since GTx-026 increased lean mass and
muscle function, we expected it to strengthen the cardiac muscle,
thereby reversing most, if not all, cardiac pathology. mdx mice
(n¼ 4/group) were castrated and treated with vehicle or GTx-026
for 10 weeks. Body weight, lean mass and grip strength measured
at the end of 10 weeks of treatment reproduced the results
observed earlier (Supplementary Material, Fig. S3).
Echocardiogram was performed to determine the architecture
and function of the hearts. Cardiac muscle function worsened in
castrated mdx mice compared with reference values for age-
matched wild-type mice. These pathological conditions were
improved by GTx-026 treatment to the reference values (Fig. 5A).
The ejection fraction (EF) in normal healthy adult mice is between
55 and 65% (49). Vehicle-treated castrated mdx mice at 16 weeks
of age exhibited an EF of 42–50%, whereas castrated mdx mice
treated with GTx-026 had an average EF of 60% (Fig. 5A).
The fractional shortening (FS) in normal adult mice is
around 30% (49). Compared with the normal adult animals’ FS
of 30, mdx mice had an average FS of 22.5%. GTx-026 treatment
improved the average FS to 30 (Fig. 5A).
While the mdx mice had aortic stenosis, animals treated
with GTx-026 did not exhibit aortic stenosis. The aortic valve
peak velocity (AVPV) is around 1500 mm/s in normal healthy
adult mice (49). While the AVPV of vehicle-treated castrated
mdx mice was around 4000 mm/s (Fig. 5A), the AVPV of GTx-026-
treated mice was in the range of 1200 mm/s. This could be
potentially due to reversal of the aortic valvular stenosis. These
results were also reflected in the aortic valve peak pressure
(AVPP). While the AVPP of vehicle-treated castrated mdx mice
was around 65 mmHg, the AVPP of mdx mice treated with GTx-
026 was around 10 mmHg (Fig. 5A). The AVPP of normal healthy
adult mice is approximately around 10 mmHg (49). When
repeated along with wild-type controls, AVPP of wild-type mice
(intact and castrated) and mdx mice (intact and castrated GTx-
026 treated) were comparable, while that of castrated vehicle-
treated mdx mice were much higher (P< 0.01) (Supplementary
Material, Fig. S4).
Histological evaluation of the heart (n¼ 4) indicated that
vehicle-treated castrated mdx mice had markedly higher fibrosis
than the GTx-026-treated mdx mice (Fig. 5B and C). This is consis-
tent with the observation of fibrosis in the gastrocnemeous and
soleus muscle of mdx mice, and with the echocardiogram results.
Castration of mdx mice significantly increased
pulmonary functional insufficiency, which were
reversed by GTx-026 treatment
Since lung failure due to lung muscle weakness is one of the pri-
mary reasons for death, we extensively evaluated the lung
Figure 3. GTx-026 improves histological markers in mdx mice. (A) Castrated mdx mice treated with vehicle or GTx-026 were sacrificed and gastrocnemius and soleus
muscle (n¼4/group) were isolated and stained with hematoxylin and eosin (H&E). Number of centrally nucleated cells (100 cells/section) were counted in 8–10 fields in
each section and represented as percent centrally nucleated cells in the bar graph. Blue arrows on the H&E stained images point to nucleus. *P<0.01. (B) GTx-026
reduces fibrosis, necrosis and inflammation. Gastrocnemius muscle (n¼4/group) from vehicle- or GTx-026-treated castrated mdx mice were fixed and stained to meas-
ure fibrosis (trichrome staining), necrosis and inflammation. The intensity of staining was scored between 0 and 3. The range is represented in the table.
Representative trichrome staining is shown in the figure. Values are represented as average 6 SE.
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Figure 4. GTx-026 increases the expression of genes important for muscle function. (A) Genes that significantly were up-regulated by GTx-026 in castrated mdx mice
are represented. Castrated wild-type or mdx mice (n¼3/group) treated with vehicle or 10 mg/kg/day s.c. GTx-026 for 12 weeks were sacrificed, gastrocnemius muscle
was isolated, RNA extracted and expression of genes was measured by RNA-sequencing. Bar graph represents the most up- and down- regulated genes. (B) Genes that
are significantly regulated in gastrocnemius muscle of castrated mdx compared with castrated wild-type mice are represented. Genes that are most up-regulated are
represented in the top bar graph panel and that are most down-regulated are represented in the bottom bar graph panel. (C). miRNAs are differentially regulated in cas-
trated mdx mice and in castrated mdx mice treated with GTx-026. RNA (n¼3/group) isolated from gastrocnemius as described in panels A&B was used to measure
genome-wide miRNA expression. MiRNAs that were differentially regulated in mdx mice compared with wild-type, but not reversed by GTx-026 are shown in the left
panel and miRNAs that were partially changed by GTx-026 in mdx mice are shown in right panel. Values are represented as average 6 SE. In (A) and (B), genes that are
2-fold between groups and have P< 0.05 and q< 0.05 are represented.
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function in castrated mdx mice treated with vehicle or GTx-026
and compared them with wild-type mice.
Wild-type or mdx mice (n¼ 4–5/group) were either sham-
operated or castrated, and treated for 10 weeks with vehicle or
GTx-026. At the end of the experiment, respiratory rate (RR),
heart rate and oxygen content were measured using MouseOx.
As shown in Figure 6A, the RR of castrated mdx vehicle-treated
mice was higher than that of the sham-operated mdx mice, indi-
cating that the castrated mice required higher breathing rate to
maintain the oxygen level in blood. This increase in RR was
reversed to the sham-operated mdx mice level by GTx-026.
Although the RR in GTx-026-treated castrated mdx mice was
lower than the vehicle-treated castrated mdx mice, the satu-
rated oxygen content in the blood was higher in GTx-026-
treated castrated mdx mice compared with vehicle-treated cas-
trated mdx mice. These indicate that the compromised lung
function in castrated mdx mice has been improved by GTx-026.
We used comprehensive laboratory monitoring system
(CLAMS) to measure the oxygen consumption and physical
activity of mdx mice. The oxygen consumed in the dark phase
Figure 5. GTx-026 reverses cardiac abnormalities in mdx mice. (A) mdx mice (n¼4/group) were castrated and treated for 10 weeks with vehicle or 10 mg/kg/day s.c. GTx-
026. Echocardiogram was performed to evaluate the cardiac anatomy and physiology. (B) GTx-026 reduces fibrosis in the heart of mdx mice. Heart (n¼4/group) from
the animals described in (A) was fixed in formalin, sectioned and stained with mason trichrome to measure the extent of collagen formation. Pathologist report is pro-
vided in the table and representative images are shown below. Values are represented as average 6 SE. *Significance at P<0.05.
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(active phase) and light phase (inactive phase) are represented
in Figure 6B, upper panel and the continuous monitoring data
are represented in Figure 6B lower panel. As shown in the figure,
the oxygen consumption (VO2) or energy expenditure was much
higher in sham-operated wild-type mice, which decreased sub-
stantially upon castration. This was obvious in both the dark
(12-h period when lights were turned-off) and light phase (12-h
period when lights were on). During the active phase (dark
phase), the oxygen consumption of sham-operated vehicle-
treated mdx mice was comparable to that of the wild-type cas-
trated mice, indicating that there was a significant reduction in
the energy expenditure in mdx mice. Castration of mdx mice
resulted in further reduction in oxygen consumption during the
active phase, which was reversed to the sham-operated level by
GTx-026 treatment. The same phenomenon was observed dur-
ing the light phase. Since muscle mass is a major component of
energy expenditure, we also accounted for the changes in lean
mass. After adjusting for changes in lean mass, there were no
significant differences in oxygen consumption. These data indi-
cate that aside from changes in lean mass, there are no sub-
stantial changes in energy expenditure.
Physical activity of the sham-operated mdx mice was much
lower than that of both the sham-operated and castrated wild-
type mice in the active phase (Fig. 6B). This was further reduced
by castration, indicating that androgens play pivotal role in the
physical activity of these mice. The physical activity was only
marginally increased by GTx-026 treatment in the active phase,
while in the light or resting phase, the physical activity was sig-
nificantly increased by GTx-026 treatment (P< 0.05). This could
mean that AR ligands are not potent enough to overcome the
existing DMD pathologies that impede physical activity during
waking hours.
To obtain conclusive results on lung function, we performed
a ventilator study with flexiventTM in mdx mice castrated and
treated with vehicle or GTx-026 for 12 weeks (Fig. 6C). Mice
treated with GTx-026 demonstrated a significant decrease in
resistance to 50 mg/ml methacholine (MeCh) compared with
mice receiving vehicle (93.0 6 8.0% vs 137.6 6 27.4%), indicating
that GTx-026 treatment improved lung function in mice. No dif-
ference was observed in the baseline resistance at 0 mg/ml
MeCh between mice treated with GTx-026 and mice receiving
vehicle (0.6 6 0.0 vs 0.6 6 0.1 cm H2O•s/ml).
To determine if the improvement in lung function is a result
of strengthened lung connective tissues, we stained the
formalin-fixed lungs from the flexivent study with mason tri-
chrome stain for collagen to determine the extent of fibrosis.
Castration of mdx mice increased the intensity of collagen stain-
ing compared with sham-operated mdx mice. This increased
intensity of staining was reversed to the sham-operated control
levels by GTx-026 treatment (Fig. 6D).
These results provide evidence that AR agonists improve
cardiopulmonary function and strengthen the heart and lungs
in castrated mdx mice.
SARMs increased the lean mass, function and survival
of dystrophin/utrn double mutant mice
Double-mutant dystrophin (Dmd) and utrophin (Utrn, a homolog
of dystrophin and a protein that partially compensates for lack
of dystrophin) (i.e. Dmd/utrn mutant) mice present a phenotype
more representative of the DMD in humans, including progres-
sive worsening of symptoms, loss of ambulation at 12 weeks,
and early death by 20 weeks. Although previous publications
have demonstrated survival of these double mutant mice up to
20 weeks, vehicle-treated castrated double mutant mice in our
studies survived only up to 9–12 weeks of age (5–8 weeks after
study initiation), indicating that androgens might potentially
contribute to the increased survival of these mice (Fig. 1). We
determined the ability of GTx-026 to increase the muscle mass
and function and subsequently survival in these mdx-dm mice.
Body weight, lean mass and grip strength of vehicle-treated cas-
trated double mutant mice all deteriorated quickly (Fig. 7A).
Treatment of these mice with GTx-026 increased all these
parameters above the baseline and maintained them till the
survival or the end of the study. These effects were translated
into survival (Fig. 7B). Vehicle-treated castrated mice survived
only between 7 and 10 weeks of age (3–7 weeks after study ini-
tiation), while SARM-treated castrated mice survived longer
with an 50–70% increase in survival (P¼ 0.000158) compared
with the vehicle-treated mice.
Discussion
The studies described herein provide evidence in support of
using AR agonists to treat DMD. The use of androgens for DMD
dates as early as 1950 when testosterone was suggested for the
use of muscular dystrophies (50). Subsequently, oxandrolone, a
steroidal synthetic androgen was evaluated in a clinical trial in
DMD boys (22). Administration of oxandrolone in 5- to 10-year-
old boys resulted in an improvement in muscle strength,
although statistically insignificant, while muscle strength of
untreated boys deteriorated. Evaluation of mechanism of action
indicated that oxandrolone increased the fractional synthesis
rate of myosin heavy chain (MHC) by 42% and upregulated
MHC8 mRNA levels in the RNA-Seq experiment.
The steroidal backbone of oxandrolone and lack of tissue
selectivity preclude the prolonged use of steroidal androgens.
With the discovery of tissue-selective SARMs, the therapeutic
potential of AR ligands can be extended to boys impaired by
DMD without concern about the side-effects on secondary sex-
ual organs. Enobosarm (GTX-024) has been evaluated clinically
in 23 completed and ongoing clinical trials (24,28). It unequivo-
cally increased muscle mass and has an impeccable safety pro-
file. One of the common side effects of androgen use, elevation
of hepatic enzymes, was also only modestly observed with GTx-
024. All these justify the advancement of a SARM to treat DMD
boys.
Currently, several treatment options are on the horizon for
the treatment of DMD. Exon skipping antisense oligonucleotides
have the ability to correct the frame-shift mutation so as to syn-
thesize a partially functional protein (51). Although this exhib-
ited early promise, one company faced regulatory set-back in
the approval process, while another company won the approval
of FDA, despite questions regarding the efficacy. Myostatin
inhibitors and utrophin up-regulators are other strategies tested
preclinicaly (52,53). Current treatment options for DMD rely on
corticosteroids to reduce inflammation. However, prolonged
use of corticosteroids results in hyperglycemia, osteoporosis
and muscle wasting, which are counterproductive in DMD.
The results presented in this manuscript demonstrate a
potential beneficial role of SARMs in DMD. Castrated male mdx
mice, which mimic androgen-depleted environment, and intact
mdx mice all responded to GTx-026. GTx-026 and other SARMs
elicited these beneficial effects at histological and molecular
level by reducing the number of centrally nucleated cells, fibro-
sis, and necrosis and significantly regulating the expression of
genes important for muscle hypertrophy.
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Figure 6. GTx-026 improves the lung function in mdx mice. (A) GTx-026 alters heart and respiratory rates (RRs) and increases blood oxygen levels. Wild-type or mdx
mice (n¼4–5/group) were castrated and treated with vehicle or 10 mg/kg/day s.c. GTx-026 for 10 weeks. At the end of the experiment, RR, heart rate (HR) and oxygen
content (SPO2) were measured using STARR Life Sciences “MouseOx” with 6.2.1 software version. All recordings were taken over 2–3 minutes with the highest SPO2%
recorded for each mouse and the corresponding HR and RR at that particular SPO2% value. (B) Energy expenditure and activity of mice were improved by GTx-026.
Wild-type or mdx mice (n¼4–5/group) were either sham operated or castrated and treated with vehicle or 10 mg/kg/day s.c. GTx-026 for 10 weeks. At the end of the
experiment, the mice were maintained in Comprehensive Laboratory Activity Monitoring System (CLAMS) for 48 h. Oxygen consumption and activity were measured
continuously for 48 h. Averages are provided in the top panels and the continuous measurements are provided in the lower panel. Dark phase is the night time when
mice are active. *Significance at P<0.01 from the respective controls. (C) Lung function is significantly improved by GTx-026 in mdx mice. Wild-type or mdx mice were
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An interesting result is the reversal of cardiomyopathy in
these mice. Although cardiomyopathy has been cited as the pri-
mary cause of death in DMD boys, aortic valvular disorder has
not been identified pre-clinically in mdx mice. This could be the
result of androgen depletion. We found a significant reduction
in overall cardiac function with EF numbers comparable to car-
diac failure. Although we lack evidence, we speculate that
weakening of cardiac muscle could be one of the multifactorial
reasons for this cardiomyopathy. GTX-026 restored anatomical,
physiological and histological deficiencies to healthy reference
control.
As the phenotype of mdx mice is mild, we also studied mdx-
dm mice that have a debilitating phenotype similar to DMD boys
to evaluate the effect of GTx-026 on survival. Although there is
evidence to suggest that these mice survive up to 20 weeks of
age, androgen depletion due to castration led to premature
death by 10–13 weeks of age. GTx-026 not only improved the
body weight, muscle mass and grip strength, but also signifi-
cantly increased survival.
The major signaling pathway, nNOS, which was found to be
deregulated in our studies in the mdx mice, has been shown to
be affected in the mdx models, validating our gene expression
data (54,55). nNOS pathway was significantly down-regulated in
the muscle of mdx mice, which was not reversed by GTx-026.
While, GTx-026 failed to reverse the genes altered by dystrophin
knockdown, it regulated the expression of genes belonging to
spermine and spermidine pathways. Interestingly, spermine
oxidase, a gene that alone is sufficient to maintain skeletal
muscle and prevent any atrophy was significantly increased
by 2–3-fold by GTx-026 in castrated mdx mice (56). Again,
genes belonging to the spermidine pathway, a product of
spermine oxidase, was also up-regulated by GTx-026.
Spermidine has been shown to be important for enhanced
cell survival. These results provide a rationale for combining
AR-targeted therapeutics with exon-skipping molecules, utro-
phin up-regulators, or myostatin inhibitors. Since these sig-
naling pathways target distinct proteins, we expect a synergy
by combining them.
Most of the muscle-specific miRNAs are modified in the gas-
trocnemeous muscle of mdx mice. These include miR-206, miR-
133 and miR-1 (57). These miRs play important roles in myogen-
esis and myoblast differentiation. It is counterintuitive to find
these miRNAs to be up-regulated in the muscle of castrated mdx
mice. It could be a compensatory mechanism to overcome the
debilitating phenotype of the loss of dystrophin. In future stud-
ies we will knock-down these miRNAs to determine if the loss
of their expression will result in a more debilitating phenotype
such as seen in mdx-dm.
castrated and treated with vehicle or 10 mg/kg/day s.c. GTx-026 for 12 weeks. Airway resistance to methacholine challenge (MeCh; Sigma-Aldrich) was measured using
the FlexiVent FX system (Scireq, Montreal, QC, Canada). Raw data were fitted into a single—compartment model and resistance data were calculated. When no signifi-
cant difference was observed in baseline values at 0 mg/ml MeCh among groups, airway resistance was normalized and presented as normalized resistance [(values –
baseline)/baseline100%]. N¼4–5/group. Data are represented as average 6 SE. *Significance at P<0.05. (D) Mason trichrome staining for collagen indicates reduced fib-
rosis in lungs from GTx-026-treated mice. Lungs from animals used in the flexivent study were fixed and stained with mason trichrome stain for collagen as a measure
of fibrosis. Stains were scored between 0 and 3 based on the intensity of stain. % SPO2, % of hemoglobin oxygenated; VO2, volume of oxygen; MeCh, methacholine.
Figure 7. GTx-026 increases body weight, muscle mass, function and survival in DMD/utrn double mutant mice. (A) dmd/utrn double mutant (mdx-dm) mice (n¼6–8/
group) were castrated and treated with vehicle or 10 mg/kg/day s.c. GTx-026. Weekly body weight, lean mass and grip strength were measured. (B) mdx-dm mice were
castrated and treated with vehicle or 10 mg/kg/day s.c. GTx-026. Animals were monitored for survival. N¼ 6–8 mice. Values are represented as average 6 SE.
*Significance at P< 0.05.
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In addition to the muscle mass and performance increase,
AR agonists such as SARMs are also beneficial in building bone
(58,59). This could be an added benefit in DMD where the boys
are not only suffering from loss of muscle mass and function,
but also undergoing extensive bone-remodeling due to either
disuse or due to chronic administration of corticosteroids.
Although the SARMs’ beneficial action in muscle are negatively
regulated by corticosteroid such as prednisolone, the interac-
tion between the two agents in bone needs to be evaluated.
Despite these beneficial effects, one limitation that needs to be
addressed is the effect of SARMs on secondary sexual organs
such as prostate. With broader selectivity between anabolic and
androgenic tissues and appropriate dose selection, this limita-
tion can be addressed to some extent.
These studies are the first comprehensive analyses of AR
signaling pathway in preclinical models of DMD. With such pos-
itive effects on multiple tissues and organs, we expect that AR
ligands such as GTx-026 could become the treatment of choice
for DMD. These molecules could be used as stand-alone or in
combination with other therapies. The magnitude of response
observed in lung and heart are compelling enough to argue that
these molecules could be very useful to extend survival when
administered to DMD patients.
Materials and Methods
All in vitro experiments were performed at least thrice and
in vivo experiments were performed with 4–10 mice/group, as
indicated in the respective figure legend.
AR transactivation
AR transactivation was performed as previously described (60).
Briefly, human AR cloned into CMV vector backbone was used
for the transactivation study. HEK-293 or undifferentiated
C2C12 cells over-expressing the AR were plated at 120 000 cells
per well of a 24-well plate in DME containing 5% csFBS. The cells
were transfected using Lipofectamine (Invitrogen, Carlsbad, CA,
USA) with 0.25 lg GRE-LUC (consensus response element that
recognizes AR), 0.02 lg CMV-LUC (renilla luciferase) and 0.025 lg
of the AR. The cells were treated 24 h after transfection as indi-
cated in the figures and luciferase assay performed 48 h after
transfection. The IC50 were obtained from four parameter logis-
tics curve.
mdx and mdx-dm animal studies
mdx and mdx-dm mice were derived from breeding DMD homo-
zygous/utrn heterozygous mice (Jackson Laboratories, Bar
Harbor, ME, USA). Genotyping was performed in accordance
with the Jackson Laboratories protocol using the recommended
primers. Male mice (4-week old) were used for the experiments.
MRI measurements were performed as indicated in the figure
using the EchoMRI (Houston, TX, USA). Grip strength measure-
ments (Columbus instruments, Columbus, OH, USA) were
recorded at various time-points as described in the respective
figure legends with both front and rear paws and the highest
value from each animal was considered. The standard operat-
ing procedure published on treat NMD website (http://www.
treat-nmd.eu/downloads/file/sops/dmd/MDX/DMD_M.2.2.001.
pdf) was used for measuring grip strength.
All animal experiments were performed under a protocol
approved by the University of Tennessee Health Science Center
(UTHSC) animal care and use committee (ACUC). Mice were sur-
gically castrated or sham operated under aseptic environment.
Briefly, the mice were anesthetized using isoflurane anesthesia
and a small incision was made in the midline of the lower abdo-
men. Testicular artery was cut to castrate the animals and the
wound closed with surgical staples. For sham surgery, the peri-
toneal cavity was exposed with an incision and closed with sur-
gical staples. Analgesic buprenorphine was provided for pain
relief.
Histology
Tissues (gastrocnemeous and soleus muscle) were collected in
10% neutral buffered formalin and stored in 4 C until further
processing. Tissues were fixed, paraffin-embedded, and 5 mm
sections were cut for staining. Immunohistochemistry and spe-
cial staining were performed using standard laboratory meth-
ods in an automated tissue processor. Sections were stained
with hematoxylin and eosin (H&E) using standard laboratory
protocol. Mason trichrome staining for interstitial collagen fiber
accumulation, which is indicative of fibrosis, was performed
according to published method (61). Slides were evaluated by a
pathologist and a score between 0 and 3 for fibrosis, necrosis
and inflammation was assigned to each slide. To determine the
number of centrally nucleated cells, approximately 100 cells
were counted in 8–10 fields from each section. Fast and slow
muscle staining were performed in gastrocnemeous muscle
(n¼ 3/group). Fast muscle was stained using anti-troponin-1
fast skeletal muscle antibody (ab134838, Abcam, Cambridge,
MA, USA) and slow muscle was stained using anti-slow skeletal
MHC antibody (ab11083, Abcam). The slides were double-
stained with red color for fast muscle and brown color for slow
muscle.
RNA-sequencing
Total RNA (1lg) was enriched for poly-AþRNA using Ambion
Dynabeads mRNA Direct Micro kit and barcoded libraries for
sequencing were prepared using the Life Technologies RNAseq V2
kit for Ion Torrent according to the manufacturer’s standard proto-
col. Libraries were amplified 14 cycles and the quality of each
library was checked on an Agilent Bioanalyzer DNA High
Sensitivity chip. The libraries were pooled based on the concentra-
tion of each sample between 200–350 bp, purified on a Pippin
Prep gel, quantified by the Agilent Bioanalyzer and sequenced on
an Ion Torrent Proton sequencer. Sequencing was performed
by University of Tennessee Health Science Center Molecular
Resources Center. The GEO number for the deposition is GSE98473.
Bioinformatics
FASTQ files were retrieved from the Ion Torrent Server at the
UTHSC Molecular Resource Center. FastQC (http://www.bioinfor
matics.babraham.ac.uk/projects/fastqc/) was run in order to
trim any bases that had a phred score<20. Once the FASTQ files
were trimmed, they were aligned to the Mus musculus nine
transcriptome using RNA-STAR (http://www.ncbi.nlm.nih.gov/
pubmed/23104886). The alignment was able to match 85% of the
raw reads on average. The SAM files were then mined for the
total read counts for each transcript. The read counts were nor-
malized to the lowest total number of reads across the experi-
ment to allow comparisons across each sample. Once
normalized, the read counts were used to calculate the average
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fold change and Student’s t-test between groupings. Only tran-
scripts that showed a fold change 1.5 and a P value0.05 were
selected. Finally, the false discovery rate (FDR) was calculated
using the Benjamini and Hochberg FDR method. Only targets
with a q value0.05 were selected for the final transcript list.
This list was uploaded to IPA for functional analysis.
CLAMS
Prior to energy expenditure measurements, mice were weighed
and total fat and fat-free mass determined non-invasively using
an EchoMRI-1100 (EchoMRITM). Mice were then individually
housed in a home cage-style Comprehensive Laboratory Animal
Monitoring System (CLAMS; Columbus Instruments) where they
had free access to food and water. Animals were maintained in
a 12:12 h light:dark cycle. Physical activity and respiratory gas
exchange were monitored over a 3-day period and values for
each of the measured variables calculated using CLAX software
(version 2.2.12; Columbus Instruments). The first 20 data collec-
tion cycles were excluded from analysis, as this was the
pre-determined CLAMS acclimation phase. Physical activity
was calculated as ambulatory movement, with the number of
consecutive beam breaks across the X and Y cage axes indicat-
ing bouts of activity. Data for the light (rest) and dark (active)
phases were separated and analyzed independently.
MiRNA expression analysis
miRNA analysis on RNA prepared from mouse tissue was per-
formed using a panel for 800 miRNAs (NanoString
Technologies, Seattle, WA, USA). In brief, total RNA was mixed
with pairs of capture and reporter probes, hybridized on the
nCounter Prep Station and purified complexes were quantified
on the nCounter digital analyzer. To account for differences in
hybridization and purification, data were normalized to the
average counts for all control spikes in each sample and ana-
lyzed with nSolver software.
Echocardiography
Using a Vevo 2100 Imaging System (Visualsonics, Toronto,
Canada) transthoracic echocardiograms were performed with
a 30 MHz transducer (MS 400; Visualsonics). Evaluations
included baseline imaging at 6 weeks of age and repeated 70
days post treatment (mice were treated for 10 weeks before
subjecting to echocardiogram). Briefly, mice were induced
with 3–5% isoflurane and fur removed with depilatory cream
(Nair, Church & Dwight Co. Inc., Princeton, NJ, USA), then
maintained with 2% isoflurane throughout the two-
dimensional and M-mode recording of the LV in parasternal
long-axis, short-axis and four chamber views. Images were
analyzed post recording using Vevo LAB software (1.7.1,
Visualsonics) with a minimum of three cardiac cycles meas-
ured for each mouse as recommended by the company. FS (%),
EF (%) and AV peak pressure (mmHg) were calculated using
standard equations within the software.
Flexivent
Airway resistance to methacholine challenge (MeCh; Sigma-
Aldrich) was measured using the FlexiVent FX system (Scireq,
Montreal, QC, Canada). Raw data were fitted into a single—
compartment model and resistance data were calculated. When
no significant difference was observed in baseline values at
0 mg/ml MeCh among groups, airway resistance was normal-
ized and presented as normalized resistance [(values – base-
line)/baseline 100%].
SPO2%
Using MouseOx (STARR Life Sciences, Oakmont, PA, USA) with
corresponding mouse thigh sensor saturated oxygen levels
were measured in all mice at week 10 after initiation of the
experiment (mice were treated for 10 weeks before subjecting to
echocardiogram). Fur was removed using depilatory cream
(Nair) over the medial thigh as recommended for mice with pig-
mented coats. All recordings were taken over 2–3 min while
under manual restraint by the same experienced lab member.
Software version 6.2.1 was used to analyze all recorded meas-
ures. The highest SPO2% recorded and the corresponding HR
and RR are presented.
Statistics
Statistical analyses were performed using JMP pro or sigmaplot
software. If two groups were used in an experiment, then the
data were analyzed by t-test and if more than two groups were
used, then the data were analyzed by one way ANOVA. Before
applying the tests for statistical significance, normality of distri-
bution was tested by the Shapiro Wilk test. Survival curves were
generated using R studio using survival library (https://rstudio-
pubs-static.s3.amazonaws.com/5588_72eb65bfbe0a4cb7b655
d2eee0751584.html). The subjects that died during the experi-
ment were censored in the plot at time of death. A number of
animals used are indicated in each figure.
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Supplementary Material is available at HMG online.
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